A phenotypic screening approach to identify anticancer compounds derived from marine fungi

Assay and Drug Development Technologies

Volumn 12, Issue 3, 2014, Pages 162-175

  Ellinger, Bernhard ^a   Silber, Johanna ^b   Prashar, Anjali ^c   Landskron, Johannes ^d   Weber, Jonas ^a   Rehermann, Sarah ^a   Müller, Franz Josef ^e   Smith, Stephen ^f   Wrigley, Stephen ^c   Taskén, Kjetil ^d,g   Gribbon, Philip ^a   Labes, Antje ^b   Imhoff, Johannes F ^b  

^a European ScreeningPort GmbH   (Germany)

^b GEOMAR HELMHOLTZ CENTRE FOR OCEAN RESEARCH KIEL   (Germany)

^c Hypha Discovery Ltd   (United Kingdom)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF KIEL   (Germany)

^f Stort MedChem Consulting Ltd   (United Kingdom)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; NATURAL PRODUCT; BIOLOGICAL PRODUCT;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; FERMENTATION; FLOW CYTOMETRY; FLUORESCENCE; FUNGAL STRAIN; FUNGUS; FUNGUS ISOLATION; MARINE FUNGI; MARINE SPECIES; MULTIPLE CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; QUANTITATIVE ANALYSIS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; MICROBIOLOGY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FUNGI; HUMANS; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME; WATER MICROBIOLOGY;

EID: 84898896199     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.564     Document Type: Article

References (39)

1. Fusetani N: Biotechnological potential of marine natural products. Pure Appl Chem 2010;82:17-26.
2. Faulkner DJ: Marine pharmacology. Antonie Leeuwenhoek 2000;77:135-145. (Pubitemid 30160413)
3. Homepage of the Clinical Pipeline of Marine Pharmacology. http://marinepharmacology.midwestern.edu/clinPipeline/html (last accessed on March 18, 2013).
4. Glaser KB, Mayer AMS: A renaissance in marine pharmacology: From preclinical curiosity to clinical reality. Biochem Pharmacol 2009;78:440-448.
5. Imhoff JF, Labes A, Wiese J: Bio-mining the microbial treasures of the ocean: New natural products. Biotech Adv 2011;29:468-482.
6. Pan JH, Gareth Jones EB, She ZG, et al.: Review of bioactive compounds from fungi in the South China Sea. Bot Mar 2008;51:179-190.
7. Raghukumar C: Marine fungal biotechnology: an ecological perspective. Fungal Divers 2008:31:19-35.
8. Blackwell M: The fungi: 1, 2, 3.5.1 million species? Am J Bot 2011;98: 426-438.
9. Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nature Rev Cancer 2006;6:813-823. (Pubitemid 44450469)
10. Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-1116.
11. Homepage of the dtp. http://dtp.nci.nih.gov/branches/btb/ivclsp.html (last accessed on March 18, 2013).
12. Niles AL, Moravec RA, Riss TL: In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening. Curr Chem Genomics 2009;3:33-41.
13. Taylor P: Analytical and preparative instrumentation. J Biomol Screen 2013; 18:143-145.
14. Oberprieler NG, Taskén K: Analysing phosphorylation-based signaling networks by phospho flow cytometry. Cell Signal 2011;23:14-18.
15. Kalland ME, Oberprieler NG, Vang T, Taskén K, Torgersen KM: T Cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J Immunol 2011;187:5233-5245.
16. Krutzik PO, Nolan GP: Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006;3: 361-368.
17. Hung PJ, Lee PL, Sabounchi P, Lin R, Lee LP: Continuous perfusion microfluidic cell culture array for high-throughput cell-based assays. Biotechnol Bioeng 2005;89:1-8. (Pubitemid 40110978)
18. Cawkill D, Eaglestone SS: Evolution of cell-based reagent provision. Drug Disc Today 2007;12:820-825. (Pubitemid 47539971)
19. Gildea JJ, McGrath HE, Van Sciver RE, Bigler Wang D, Felder RA: Isolation, growth, and characterization of human renal epithelial cells using traditional and 3D methods. Methods Mol Biol 2013;945:329-345.
20. White TJ, Bruns T, Lee S, et al.: Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: PCR Protocols: A Guide to Methods and Applications. Innis MA, Gelfand DH, Sninsky JJ, et al. (eds.), pp. 315-322. Academic Press, New York, 1990.
21. Laatsch H (ed.): AntiBase - The Natural Compound Identifier. Wiley-VCH, Weinheim, Germany 2007.
22. Buckingham J, Ayres DC (ed.): Dictionary of Natural Products. Chapman & Hall/ CRC Press, Taylor & Francis Group, London, 2009.
23. Repetto G, del Paso A, Zurita JL: Neutral Red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008;3:1125-1131.
24. Gribbon P: High-throughput hit finding and compound-profiling technologies for academic drug discovery. Drug Discovery Today: Technologies 2008;5:e3-e7
25. Boyd MR, Paull KD, Rubinstein LR: Cytotoxic Anticancer Drugs:Models and Concepts for Drug Discovery and Development. Kluwer Academic, Hingham, MA, 1992.
26. Krutzik PO, Clutter MR, Trejo A, et al.: Fluorescent cell barcoding for multiplex flow cytometry. Curr Protoc Cytom 2011, Chapter 6: Unit 6 31.
27. Hendzel MJ, Wei Y, Mancini MA, et al.: Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-360. (Pubitemid 27510848)
28. Schneider U, Schwenk HU, Bornkamm G: Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977;19:621-626. (Pubitemid 8094638)
29. Seshacharyulu P, Ponnusamy MP, Haridas D, et al.: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012:16:15-31.
30. O'Shea JJ, Holland SM, Staudt LM: JAKs and STATs in Immunity, Immunodeficiency, and Cancer. N Engl J Med 2013;368:161-170.
31. Lappano R, Maggiolini MG: protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10:47-60.
32. Silber J, Ohlendorf B, Labes A, et al.: Calcarides A-E, antibacterial macrocyclic and linear polyesters from a calcarisporium strain. Mar Drugs 2013;76:1461-1467.
33. Ka Yan Chan G, Kleinheinz TL, Peterson D, Moffat JG: A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS ONE 2013;8:e63583.
34. Luo J, Yang ST: Effects of three-dimensional culturing in a fibrous matrix on cell cycle, apoptosis, and MAb production by hybridoma cells. Biotechnol Prog 2004;26:306-315. (Pubitemid 38204203)
35. Kim J: Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005;15:365-377.
36. Zhang JY, Tao LY, Liang YJ, Yan YY, Dai CL, Xia XK, She ZG, Lin YC, Fu LW: Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with involvement of GSK-3beta/beta-catenin/c-Myc pathway. Cell Cycle 2009;8:2444-2450.
37. Sun Y, Kentaro T, Takemoto Y, Yoshida M, Nogi Y, Okada S, Matsunaga S: Gliotoxin analogues from a marine-derived fungus, Penicillium sp., and their cytotoxic and histone methyltransferase inhibitory activities. J Nat Prod 2011;75:111-114.
38. Scherf U, Ross DT, Waltham M, et al.: A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-244. (Pubitemid 30132190)
39. Ross DT, Scherf U, Eisen MB, et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-235. (Pubitemid 30132189)